Back to top
more

Masimo (MASI)

(Delayed Data from NSDQ)

$143.49 USD

143.49
736,466

+3.55 (2.54%)

Updated Oct 9, 2024 04:00 PM ET

After-Market: $143.53 +0.04 (0.03%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Medical Product Stock Earnings on May 2: CERN, ABC & More

by Zacks Equity Research

Given the solid prospects in the U.S. medical products industry, here we take a peek at four major Medical Product companies scheduled to report results on May 2.

    Masimo Gets CE Mark for NomoLine, Expands in Capnography

    by Zacks Equity Research

    Masimo (MASI) upgrades respiratory monitoring through the newly-approved Rad-97 Pulse Co-Oximeter with integrated capnography sampling lines.

      Why Masimo (MASI) Could Beat Earnings Estimates Again

      by Zacks Equity Research

      Masimo (MASI) can be a harbinger of outperformance and a signal for a strong earnings profile on the back of solid Zacks rank and positive earnings ESP.

        Masimo (MASI) Launches UniView, Improves Patient Safety

        by Zacks Equity Research

        Masimo's (MASI) strategy to target hospitals and consumer market is likely to provide it a competitive edge in the U.S. MedTech sector.

          Here's Why You Should Invest in Masimo (MASI) Right Now

          by Zacks Equity Research

          Masimo (MASI) rides on solid earnings results and a wide array of products.

            Masimo (MASI) Beats on Q4 Earnings & Revenues, View Positive

            by Zacks Equity Research

            Strong performance in Product revenues drove Masimo's (MASI) fourth-quarter 2017 results.

              Masimo Products to Boost India-Based NU Hospitals' Systems

              by Zacks Equity Research

              Masimo's (MASI) flagship technologies to be incorporated in India-based NU Hospitals' continuum of care.

                Masimo's SpHb Hemoglobin Monitoring Study Results Positive

                by Zacks Equity Research

                New study proves that Masimo's (MASI) noninvasive SpHb is more efficient in hemoglobin monitoring when compared to invasive LabHb.

                  Masimo's (MASI) Eve Gets CE Mark, Bolsters CCHD Diagnosis

                  by Zacks Equity Research

                  Masimo's (MASI) newborn screening application, Eve, will make CCHD diagnosis simple and cost effective.

                    Masimo (MASI) Receives FDA Approval for SedLine, Shares Up

                    by Zacks Equity Research

                    Masimo (MASI) to overhaul neurological diagnoses with its next generation SedLine brain function monitoring.

                      Masimo Gets FDA Nod for Rad-97, Enables Healthcare at Home

                      by Zacks Equity Research

                      Masimo (MASI) states that with its inherent touchscreen interface, Rad-97 is user-friendly for clinicians and non-clinicians and can be easily tailored to cater to the needs of home users.

                        Cogentix (CGNT) Stock Near 52-Week High: More Room to Run?

                        by Zacks Equity Research

                        Cogentix Medical (CGNT) stock continues to hover around the 52-week high mark reached on Dec 27, courtesy of its new strategies.

                          Robust Pipeline Aids Edwards Lifesciences, Rising Costs Ail

                          by Zacks Equity Research

                          Edwards Lifesciences' (EW) pipeline building to fortify foothold across all operating businesses bodes well. Also, the TAVR adoption rate across Japan and the European countries is impressive.

                            Align Rides on Balanced Segmental Growth Amid Stiff Contest

                            by Zacks Equity Research

                            Align (ALGN) gains from balanced sales growth across all its channels of late, primarily on high InvisAlign Technology case volumes.

                              Here's Why You Should Invest in Masimo (MASI) Right Now

                              by Zacks Equity Research

                              Masimo (MASI) rides high on its solid guidance. The company's recent FDA approval is also encouraging.

                                The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies

                                by Zacks Equity Research

                                The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies

                                  5 MedTech Stocks to Beat Tax Hazards With Positive Returns

                                  by Zacks Equity Research

                                  Trump's tax reform policies promise to cut corporate taxes. However, the future of the U.S. MedTech industry depends on the much-awaited decision on the 2.3% medical device tax.

                                    Here's Why You Should Invest in Masimo (MASI) Right Now

                                    by Zacks Equity Research

                                    Masimo (MASI) continues to grow on innovation and product launches.

                                      Masimo (MASI) Beats on Q3 Earnings and Revenues, Raises View

                                      by Zacks Equity Research

                                      Masimo (MASI) raises fiscal 2017 guidance. The year-over-year increase in both revenues and earnings encourages.

                                        Masimo (MASI) Launches Trace Data and Reporting Tool in US

                                        by Zacks Equity Research

                                        Masimo's (MASI) launch of Trace in the United States will aid the company in capturing the growing patient data visualization market.

                                          AmerisourceBergen's PharMEDium Slows Down, Competition Rife

                                          by Zacks Equity Research

                                          AmerisourceBergen'S (ABC) growth story is expected to be stunted by tepid performance at PharMEDium. Also steep competition is a cause of concern.

                                            Amedisys' Arm Buys Intercity Home Care, Boosts U.S. Base

                                            by Zacks Equity Research

                                            Amedisys' (AMED) encouraging efforts put the Personal Care business on growth track. This segment lives up to a strong performance with the integration of several recent tuck-in acquisitions.

                                              Abbott to Gain from Alere's Takeover Due for Oct 3 Closure

                                              by Zacks Equity Research

                                              Alere's acquisition would help Abbott (ABT) explore new channels and geographies, including forays into fast growing outlets like doctors' offices, clinics, pharmacies and at-home testing.

                                                Masimo RAS-45 Full-Market Release to Boost Respiratory Care

                                                by Zacks Equity Research

                                                Masimo Corporation's (MASI) newly launched RAS-45, a single use adhesive respiration sensor would strengthen the company's foothold in the growing global respiratory care market.

                                                  Here's Why Investors Should Buy Masimo (MASI) Right Now

                                                  by Zacks Equity Research

                                                  Masimo (MASI) announced 510(k) clearance and full-market release of its proprietary Rad-97 Pulse CO-Oximeter earlier this month.